Cargando…

Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies

Targeting T cell receptor β-chain constant region 1 (TRBC1) CAR-T could specifically kill TRBC1+ T-cell malignancies. However, over-expressed CARs on anti-TRBC1 CAR transduced TRBC1+ T cells (CAR-C1) bound to autologous TRBC1, masking TRBC1 from identification by other anti-TRBC1 CAR-T, and moreover...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Chaoting, Palashati, Heyilimu, Rong, Zhuona, Lin, Ningjing, Shen, Luyan, Liu, Ying, Li, Shance, Yu, Bentong, Yang, Wenjun, Lu, Zheming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679992/ https://www.ncbi.nlm.nih.gov/pubmed/33218364 http://dx.doi.org/10.1186/s12943-020-01282-7

Ejemplares similares

Evaluation of Molecular Simulations and Deep Learning Prediction of Antibodies’ Recognition of TRBC1 and TRBC2
por: Zeng, Xincheng, et al.
Publicado: (2023)

Computational discovery of binding mode of anti-TRBC1 antibody and predicted key amino acids of TRBC1
por: Saetang, Jirakrit, et al.
Publicado: (2022)

PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma
por: Wang, Chunyan, et al.
Publicado: (2022)

Emerging Role of T-cell Receptor Constant β Chain-1 (TRBC1) Expression in the Flow Cytometric Diagnosis of T-cell Malignancies
por: Horna, Pedro, et al.
Publicado: (2021)

TRBC1在成熟T细胞淋巴瘤中的表达特点及诊断价值
Publicado: (2022)

Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation
por: Muñoz-García, Noemí, et al.
Publicado: (2021)

High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in Tαβ-Large Granular Lymphocytic Leukemia
por: Muñoz-García, Noemí, et al.
Publicado: (2022)

Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience
por: Capone, Manuela, et al.
Publicado: (2022)

Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
por: Tan, Qin, et al.
Publicado: (2019)

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
por: Zhang, Chaoting, et al.
Publicado: (2021)

Autophagic flux restoration of senescent T cells improves antitumor activity of TCR‐engineered T cells
por: Zhang, Chaoting, et al.
Publicado: (2022)

Autophagic flux restoration enhances the antitumor efficacy of tumor infiltrating lymphocytes
por: Zhang, Chaoting, et al.
Publicado: (2022)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity
por: Gupta, Sasha, et al.
Publicado: (2023)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The difference and relationship of CD4+ and CD8+ tumour infiltrating lymphocytes in lung adenocarcinoma
por: Zhang, Chaoting, et al.
Publicado: (2019)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Current state of CAR-T therapy for T-cell malignancies
por: Luo, Liangkui, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
por: Yang, Mingya, et al.
Publicado: (2020)

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
por: Viaud, Sophie, et al.
Publicado: (2018)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
por: Mehta, Palak H., et al.
Publicado: (2021)

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
por: Klampatsa, Astero, et al.
Publicado: (2020)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
por: Takahashi, Takuto, et al.
Publicado: (2022)

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
por: Brechbühl, Simon, et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies
por: Jie, Yamin, et al.
Publicado: (2021)

CAR T-cell immunotherapy of B-cell malignancy: the story so far
por: Halim, Leena, et al.
Publicado: (2020)

Base-edited CAR T cells for combinational therapy against T cell malignancies
por: Georgiadis, Christos, et al.
Publicado: (2021)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i7h64k0oghrr5oh6qhbvg2119g